Sign Up

About ARALAST NP Therapy

ARALAST NP ARALAST NP

ARALAST NP Therapy Tolerability

ARALAST NP therapy is a similar product to ARALAST therapy, containing the same active components of plasma α1-PI with identical formulations.1

In a PK (pharmacokentic) study, no serious side effects, anitbody formation, and seroconversions were observed.1

Important Risk Information for
ARALAST NP

  • The most common adverse events deemed related to ARALAST NP included: headache (4 of 61 [7%] events) and musculoskeletal discomfort (4 of 61 [7%] events).
  • ARALAST NP is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15 mg/dL) who have known antibody against IgA, since they may experience severe reactions, including anaphylaxis to IgA, which may be present in small quantities in the final drug product.
  • ARALAST NP is derived from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Please review the Important Risk Information and the Full Prescribing Information

Please review the Important Risk Information and the Full Prescribing Information

References

  1. ARALAST NP [Alpha1–Proteinase Inhibitor (Human)] Prescribing Information, Baxter Healthcare Corporation; May 2007.